Purpose: A number of independent gene expression profiling studies have identified transcriptional subtypes in colorectal cancer (CRC) with potential diagnostic utility, culminating in publication of a CRC Consensus Molecular Subtype classification.
current molecular classification dogma and highlighting the need to consider pathology sampling region and degree of stromal infiltration when employing transcription-based classifiers to underpin clinical decision-making in CRC.
Translational relevance: Recent molecular profiling studies in CRC have identified distinct subgroups with significant prognostic value. These studies have proposed the use of transcriptional-based companion diagnostic tests, based on these prognostic subgroups. In stage II/III CRC, such diagnostic tests are urgently needed to inform clinical decision-making in regard to administration of adjuvant therapy following surgery. The identification of a poor prognostic group has been associated with EMT-and Stem-like traits, although detailed analysis of these tumors has revealed that the stromal-rich architecture of the tumor microenvironment informs their biology. In this study, we highlight the contrasting gene expression at multiple regions of CRC primary tumors due to intratumoral heterogeneity. This differential biology itself displays prognostic value and overlaps with the proposed diagnostic classifier signatures in CRC. Further to this, we highlight the potential for individual patient misclassification due to this regional heterogeneity using the recently proposed molecular classifiers.
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INTRODUCTION
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the Western world. To date, the most powerful prognostic classification tool in CRC still relies on the Tumor Node Metastasis (TNM) staging system. While histopathology is able to identify a number of factors which provide additional prognostic value and capture biological aspects of important disease processes, (such as tumor morphology, grade and stage, lymphovascular invasion and peritumoral inflammation), it gives no insight into the distinct biology that underpins CRC and determines disease outcome.
We and others have employed transcriptional profiling of clinically-annotated tumor samples to gain molecular insights into CRC biology and thereby develop new patient stratification tools and identify novel therapeutic approaches (1) (2) (3) (4) (5) (6) . Using unsupervised classification of transcription data, independent groups have reported 3-6 molecular subgroups within CRC (2, 4, 7) . Recent subtype concordance analysis by the CRC Subtyping Consortium (CRCSC) has yielded a consensus of 4 transcriptionally-driven CRC molecular subgroups (Consensus Molecular Subtype (CMS 1-4)) with the following distinguishing features: CMS1: Microsatellite instable(MI)/immune (frequency(f) =14%); CMS2: Canonical (f=37%); CMS3:
Metabolic (f=13%) and CMS4: Mesenchymal (f=23%) (8, 9) . Of these subgroups, the mesenchymal subtype (CMS4) has been found to be significantly associated with the worst prognosis in all studies. Additionally, this gene signature has also been detected in serrated precursor lesions, suggesting that aggressive tumor traits may be "imprinted" in dysplastic tissue at the very earliest stage. Many of the studies highlighted above (2, 4, 7) suggested that the identification of the CMS4 subtype was evidence of epithelial tumor cells undergoing changes associated with an extensive epithelial-mesenchymal transition (EMT), resulting in increased invasion and the acquisition of stem cell properties that are necessary for the establishment of metastases (10) . Although the findings of these studies were independently validated, the cells-of-origin of individual transcriptional subtypes were not defined. More recently, two studies have indicated that mesenchymal tumors have an enriched stromal component, suggesting that the origin of the CMS4 signature may be dependent on the transcriptional profile originating from the stromal rather than the tumor compartment (11, 12) . In this paper, we build on these recent studies and provide important insights into the role of the colorectal tumor stroma, which may have significant implications for transcription-based classifiers as precision medicine tools for patient stratification. 
Materials and Methods

Tissue samples
Upon receipt in the histopathology laboratory, fresh colon resection specimens (resected for tumor) were examined by a pathologist. Regions of interest (deep and superficial tumor) were identified using standard approaches and described for subsequent sampling. Specimens were then fixed in 10% neutral buffered formalin, sampled and processed as per routine histology. Subsequent examination of 3 µm H&E stained sections confirmed the presence of the identified regions of interest and examination of further material from the same resection identified lymph nodes positive for tumor metastasis. The areas to be sampled were marked on the slides by a pathologist and these were then used as a guiding template for macrodissection of 10 µm unstained tissue sections cut from the same block. Tissue of interest was scraped off the slide using a scalpel and a small amount of ethanol and placed in a labelled micro-centrifuge tube.
Sample analysis
We selected samples from 25 patients (for clinical details see Supplemental Table 1) where we had sufficient high quality material to extract RNA from regions of interest. 
Data analysis and classifier generation
DSA arrays were read into the R statistical environment (version 3.1), background corrected and normalized using the justRMA function in the affy package. We initially assessed the profiles for dissimilarities by bootstrap hierarchical clustering to assess confidence in the groups and their distances by pvclust, allowing also for various non-specific gene filtering levels by the package genefilter. From here, the limma package was used to assess MDS plots as well as to perform differential expression analysis between contrasts and generation of the overlap by Venn diagram. In order to create a succinct list of genes that could best classify the central region against the invasive front, we adopted a machine learning method, pamr. Groups were stratified randomly into a three quarter training set and one quarter test set. We used genefilter's 'varFilter' method to reduce the complexity of the features, which we also repeated for the pamr process at increasing stringencies to increase confidence in the list generated. We performed pamr analysis using a ten-fold cross-validation and chose our threshold to select the lowest misclassification rate (t= 2.0, misclassification = 5/36 and an overall error rate = 0.138). Using our initial classification run, pamr proffered a list of 58 features equating to 30 annotated genes. This annotated gene list formed the benchmark for dataset stratification in other independent datasets for the rest of this study. Hierarchical clustering performed in R was done using heatmap.plus using the Ward clustering method with Euclidean distance and with ordination of the data performed using correspondence analysis with the package made4 and visualized using the plotarrays parameter with differing graph arguments. GSE35602, GSE33113, GSE39396 and GSE39582. In addition, the independent mouse dataset was accessed under GSE6383. Partek Genomics Suite was used on these series matrix files for independent dataset analysis. For the purpose of clustering, the data matrices were standardized to the median value of probe sets expression. Standardization of the data allows for the comparison of expression levels for different probe sets', which may not necessarily be on the same scale or at the same intensity levels. Following standardization, 2-dimensional hierarchical clustering was performed using the Ward clustering method with Euclidean distance. 
Statistics
RESULTS
Identification of region-specific transcriptomic profiles:
In order to assess tumor heterogeneity at the level of transcription, we performed gene expression profiling on a cohort of patients (n=25, Supplementary Table 1) using tumor samples taken from multiple regions of the primary tumor, in addition to tumor tissue which had metastasized to regional lymph nodes ( Supplementary   Figure 1 ). The resulting transcriptomic data were analyzed using limma to identify differentially expressed genes. A supervised learning approach, pamr, was employed to extract a succinct list of genes that could highlight the contrasts between samples from different regions, which could then be visualized using a combination of a heatmap and hierarchical clustering.
Determination of the number of genes which were differentially expressed (DE) between each region indicated that the transcriptome of the central tumor (CT) was more closely related to that of the invasive front (IF) than to that of the lymph node (LN) tumor tissue ( Figure 1A and Supplementary Tables 2-4 ). However, both limma and pamr analyses revealed distinct differences between gene expression in the CT and IF, with a consistent upregulation of known drivers of disease progression, such as IGF1 (2.3-5-fold) and SFRP2 (2.6-4-fold) at the IF region, while upregulation of CXCL5 (3.3-8-fold), IL8 (3.6-4.4-fold) and MMP1 (2.6-7.9-fold) were consistently found in the CT region ( Figure 1B , Supplementary Table 2 ).
Using pamr classification, we extracted a concise gene list, comprising 30 annotated genes, that could identify and characterize the transcriptome associated with a minimum overall error (error rate = 0.138, Table 1 ). As expected, this gene list on May 9, 2016. © 2016 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on May 5, 2016; DOI: 10.1158/1078-0432.CCR-16-0032 contained a number of genes already reported to be involved in cancer progression, many of which were also represented in the DE gene list (Supplementary Table 2 ), such as IGF1, TGFB3, IL8, IL1B and WNT5A. We validated the gene list by applying it to the full cohort of IF and CT samples ( Figure 1C ) using hierarchical clustering to visualize ranges of expression. The region-of-origin was correctly identified in 44 out of 48 samples, giving this classifier a positive prediction value (PPV) for membership of IF equal to 91.7% and a corresponding negative prediction value (NPV) for membership of CT equal to 91.7%.
Specific gene signatures identify tissue regions of origin
To test the ability of stromal gene expression to classify tumor samples, we utilized a list of 213 genes, which are specifically expressed in cancer-associated fibroblasts (CAFs) (n=131), leukocytes (n=47) or endothelial cells (n=35) (11) . Using this gene list, the samples from LN, CT and IF could be separated into 3 biological groups corresponding to their site of origin, using correspondence analysis of the top quartile most variant probes ( Figure 2 ). Whereas Isella et al. (11) and Calon et al. (12) have shown that these 213 non-epithelial genes can be used to identify poor prognostic patients, we now demonstrate that the same genes can be used to identify the site of the tumor from which the sample has been taken. Moreover, the 30 gene list (which we now define as a stromal classifier) was also able to correctly distinguish between tumor and stroma tissues in a cohort of 13 CRC tumor samples (GSE35620), each of which was micro-dissected into these two components, with no misclassification ( Figure 3A, 3B ). As a further validation, we used a tissue-specific dataset (GSE6383), which identified genes expressed in the mesenchymal and epithelial compartments of the perinatal mouse intestine (13). This analysis revealed that the genes which we found to be overexpressed in IF compared to CT are highly expressed in the stromal mesenchyme fraction of the developing mouse intestine compared to the epithelium, and can stratify samples into regions of origin with no misclassification ( Figure 3C ). Collectively, these findings indicate that our 30 gene stromal classifier is an accurate identifier of tissue origin.
To further delineate the source of the identified transcriptional signals to a precise cell-of-origin, we utilized microarray profiles derived from primary CRC tumors which have undergone disassociation and sorting in order to isolate cells into epithelial, endothelial, fibroblast and leukocytes compartments (GSE39396). Hierarchical clustering of our classifier using these cell sorted profiles indicated the upregulation of each transcript signal specifically in the fibroblast component, compared to the remaining tumor cell types ( Figure 4A ). Following median normalization for each individual gene across all four cell types, we again confirmed that the upregulation of the transcription levels for our classifier occurs specifically within the fibroblasts, compared to all other cell types ( Figure 4B ).
The 30 Gene Stromal Classifier overlaps with the CMS4 subtype
We next interrogated an independent stage II/III colon cancer dataset (2) . Using a semi-supervised clustering approach, we identified a subset of tumors accounting for 20% of the overall cohort that were positive for the 30 gene Stromal Classifier. Of these tumors, almost 90% are associated with the previously reported stem-like (CMS4) poor prognostic group (2) ( Figure 5A ). These findings show that the genes which are differentially expressed between the central and invasive front regions of a primary tumor can identify patients exhibiting a poor prognostic "stem cell-like" (14) ) and GSE33113 (an untreated stage II dataset (7)), the 30 gene Stromal Classifier consistently identified patients with a poorer prognosis, although these associations just failed to reach significance, most likely due to limited sample numbers ( Figure 5B ).
To assess the extent that patient classification can be dictated by the tumor region sampled, we performed a reciprocal in silico analysis, in which the 48 samples representing IF and CT were classified using the genes previously published to classify the stem-like mesenchymal subtype (2). This analysis revealed 2 separate clusters, both highly enriched for samples based on the region-of-origin, with 75% of profiles originating from the IF being classified as stem cell-like ( Figure 5C ), compared to 33% for CT. 
Discussion
Region-specific transcriptional profiling allows precise dissection of the role of different tissue compartments in CRC disease biology, while also providing prognostic information on individual patients. Our results from 2 independent datasets GSE35620 ( Figure 3A , 3B) and GSE6383 ( Figure 3C ) are in line with the recent stromal studies reported (11, 12) and further confirm that the key genes involved in classification of patient samples are derived from a stromal origin. These data collectively challenge the general assumption that tumors classified as mesenchymal, or in the CMS4 subgroup, have undergone widespread EMT, resulting in lower levels of epithelial associated traits in the tumor cell compartment, when actually these tumors have a higher component of stromal (particularly fibroblast), infiltration. Although immunohistochemistry-based analysis of CRC tumors has shown that neoplastic epithelial cells expressing stem-like properties have a poor prognosis (15) (16) (17) , our findings emphasize that the CMS4 subgroup represents tumors with higher transcription levels of mesenchymal-associated genes, which can be attributed to their overall stromal-rich, and in particular fibroblast, architecture.
While our data strongly suggest that the overall proportion of EMT in CMS4 tumors is not as extensive as first proposed, we did observe some evidence of localized loss of E-cadherin staining in a small proportion of budding cells (data not shown). configuration of the tumor border region itself can also give insight into the prognosis of a patient, with a high degree of stromal infiltration into a tumor being a poor prognostic indicator (18, 19) .
While the finding that high levels of stromal infiltration are associated with poor prognosis is not new (11, 12, 18, 19) , the present study precisely delineates the cellof-origin to the fibroblast compartment, with primary results validated in a comprehensive series of online datasets. Data presented here, in addition to these referenced studies (12, (18) (19) (20) highlight that expression of a small number of genes in fibroblasts associated with the tumor, in combination with the overall fibroblast content, is sufficient to identify poor prognostic patients in stage II CRC. It is unsurprising therefore that the prognostic value of the CMS4 subtype, and indeed other current transcriptional-based prognostic classifiers, is highly dependent on stromal-derived gene signatures and that our 30 gene Stromal Classifier also identifies a group of patients with a worse prognosis. A combined classification system, utilizing clinical, morphological and molecular features, has been previously proposed and shown to provide a confident prediction of patient outcome (21) . Multiregion sequencing and mutational analysis has highlighted diversity in renal (22) and recently in CRC (23) patient samples, but our data shows that patient classification in CRC utilizing transcriptional profiling is associated as much with the region from where the sample is derived from, as with the underlying tumor biology.
Implications of transcriptomic heterogeneity within CRC
Data presented here shows for the first time that the recently published CRC CMS classification system (9) is dependent not just on the overall driving biology of a tumor, but also on the region of sampling. We have shown that each individual primary tumor has the potential to be classified into a poor prognostic mesenchymal subtype if the tissue employed in the analysis is taken from the invasive front of the tumor, regardless of the inherent CMS subtype of the tumor overall. These findings may have important implications for the use of molecular classification approaches in selecting patients for therapeutic intervention in biomarker-driven stratified clinical trials. Given the lack of standardized procedures employed in tissue sampling for these transcriptional profiling approaches, our data provide cautionary evidence that a generic transcriptional profiling strategy, which does not consider the role of specific site of tissue origin within the tumor, could result in patient misclassification into inappropriate subgroups, leading to inaccurate prognostication and treatment that yields no benefit or may even potentially harm patients.
A recent precision medicine-based clinical trial, the WINTHER study (24, 25) (an output of the Worldwide Innovative Networking in personalized cancer medicine (WIN) Consortium), aimed at selecting optimal innovative drug treatment strategies for patients with advanced metastatic tumors, has highlighted the utility of sampling matched normal and tumor biopsies from the same patient in order to identify novel therapeutic strategies based on differential gene expression in the neoplastic tissue compared to the normal sample. There are a number of clear similarities between the WINTHER study approach and the findings presented here, where the non-tumor component can inform prognosis, but while there seems to be clear rationale for this approach aimed at personalized drug selection, there may be only limited benefit derived by subtracting the results of adjacent normal or stromal tissue in order to correctly classify the overall tumor molecular subtype. As the defined CMS of CRC The primary tumor samples used in this study are predominantly from patients with non-metastatic disease (92% stage II/III - Supplementary Table 1 ) and as such represent samples with limited molecular heterogeneity compared to pretreated metastatic solid tumor samples or samples from advanced leukemia patients (e.g. blast crisis Chronic Myeloid Leukemia (CML)), both of which can introduce further complicating issues when assessing prognosis and treatment response using molecular-based precision medicine approaches (26) . While there is, as yet, no defined metastatic-specific CMS typing approach which captures transcriptional changes associated with liver and lung tissue infiltration, there will inevitably be variations in the stromal content of metastatic lesions in both the liver and lung similar to what we have presented here in the primary setting. The prognosis of tumors with high metastatic site-specific stromal infiltration may not equate to that of high levels of fibroblast infiltration in primary CRC tumors, and in a similar scenario to blast crisis CML, it is clear that putative treatment regimes for molecularly heterogeneous metastatic neoplastic lesions from solid tumors require very careful consideration in order to achieve therapeutic success (26 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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